CD8B and neoplasm: To determine whether the delay in resistance mediated by ECM inhibition was CD8+ T cell–dependent, we treated YUMM1.7 tumor‐bearing mice with DHB and concurrently depleted CD8+ T cells using an anti‐CD8b antibody (Figure 7C).